Stocks Charged Up On ASX – IVX, BKY, IP1

Stocks Charged Up On ASX - IVX, BKY, IP1

IVX:

Invion Limited (ASX: IVX) is a drug delivery company. It leads the global research and development of PhotosoftTM technology, to cure different types of cancer.

The Hudson Institute of Medical Research, IVX’s research partner, completed the initial in vivo trials in the animal models. This was done with the aim to check the acceptance, localisation and clearance from the tumour tissue of IVX-P02, the company’s photosensitiser. The findings suggested that IVX-P02 could play a significant role to treat metastatic cancer. Besides this, the use of IVX-P02 to treat ovarian cancer are being studied.

As per its March quarter update, the company received $1.4M in R&D services income through its R&D Services Agreement with The Cho Group. The pre-clinical work for the Phase 1b trial for BCC was back on track and the data is expected in Q4 2019. Its completion would pave the way towards a pivotal human trial for Basal Cell Carcinoma and Actinic Keratosis before the end of the calendar year 2019. The BCC and AK markets are worth $703 million, in Australia alone.

IVX’s cash flow highlighted in the below table:

Cash Flow Amount (A$’000)
Net cash used in operating activities (154)
Cash and equivalents at the end of the quarter 485
Estimated cash outflows for next quarter 1,607

As on 28th May 2019, the stock of the company last traded at A$0.018, zooming up by 28.57% from its previous close.

BKY:

Berkeley Energia Limited (ASX: BKY) is a clean energy company. At present, its focus is to get its wholly owned Salamanca project, a uranium project into the production phase. The company was awarded the Sustainable Mining and Environmental Excellence by AENOR.

Operations at Salamanca project (Source: Company website) –

In its quarterly update for Q119, the company announced various favourable assessments from various regulatory bodies relating to the pre-operational Surveillance Plan for Radiological and Environmental Affections and the pre-operational Surveillance Plan for the Control of the Underground Water. The report from the Nuclear Safety Council is awaited.

The uranium market continued to remain strong with growing demand outlook. BKY has 2,750,000 pounds worth of U3O8 under agreement for the initial six years, with an additional 1,250,000 pounds of optional volume. This is averagely priced per pound over $42.

The company held a total cash balance of A$97 million by the close of March 2019 quarter period. Below are the cash flow highlights:

Cash Flow Amount (A$’000)
Net cash used in operating activities 2,030
Net cash used in investing activities 6
Cash and equivalents at the end of the quarter 97,369
Estimated cash outflows for next quarter 2,750

 

As on 28th May 2019, the stock of the company closed at a price of A$0.345, rising by 30.18% from tis previous close.

IP1:

Integrated Payment Technologies Limited (ASX: IP1) is a financial technology player in the Australian market. The company deems itself to be the leader in integrated electronic payment remittance.

The company launched a 1 for 1 non-renounceable pro-rata entitlement offer of shares with the aim to raise up to $1.544 million at an offer price of $0.01 per share on 10th April 2019. Later on 12th April, it declared the completion of the Institutional Entitlement Offer and raised almost $770,000.

The company closed the offer on 20th May after it was oversubscribed by its retail shareholders. The total funds received amounted to $893,812.19. $120,316.81 of these were returned to shareholders, because of a scaleback of applications.

Also, the company released its March quarter report on 2nd May 2019. IP1 had launched PayVu to bookkeepers and accountants. PayVu decreases cybersecurity risk and provides a separation of duties while also reducing low-value contact from the payment process for all shareholders.

Besides this, ClickSuper Single Touch Payroll, which aids to transfer the private information safely, inherent in the STP and SuperStream processes, witnessed growth.

The total cash in hand with IP1 amounted to $546,343. Other financials are described in the chart below:

Consolidated P/L account for the 3 months ending 31st March 2019 (Source: Company’s report)

As on 28th May 2019, the stock of the company closed at a price of A$0.025, up by 13.63% from its previous close.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Checkout our Free Dividend Stocks Report

Specially made for income-hungry investors, Invest in growing Franked Dividends an opportunity that should not be missed.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report